Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Jul 30, 2021 (5 years ago)

Combipatch

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Stability Specifications; out of specification for shear.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Combipatch (estradiol/norethindrone acetate transdermal system) 0.05/0.25 mg per day 50/250 Twice Weekly Rx Only a) 2 Systems NDC 68968-0525-2; b) 8 Systems NDC 68968-0525-8, Mfd. by: Noven Pharmaceuticals, Inc., Miami, Florida 33186, Dist. by: Noven Therapeutics LLC, Miami, Florida 33186

Affected NDCs 68968-0525-02 68968-0525-08

Compare with the code on your package — it is the most precise check available.

Drug: Estradiol

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
CombiPatch (estradiol/norethindrone acetate transdermal system)
estradiol/norethindrone acetate transdermal system
NDC 68968-0525
ESTRADIOL .05 mg/d; NORETHINDRONE ACETATE .25 mg/d Patch, Extended Release
Transdermal
Noven Therapeutics, LLC Rx
Recalling firm
Noven Pharmaceuticals Inc
NDC code
68968-0525-2
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0725-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Estradiol recalls

See all
Class II · Moderate risk

Alyacen 7/7/7

Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.

Ongoing Impurity / degradation Glenmark Pharmaceuticals Inc., USA NDC 68462-556-29 D-0588-2026
Class II · Moderate risk

Estradiol Gel

Defective Container; packets were found to be either empty or partially full.

Ongoing Packaging defect ANI Pharmaceuticals, Inc. NDC 70954-531-20 D-0543-2026
Class II · Moderate risk

Estradiol

Presence of Foreign substance - potential presence of metal particulate matter

Ongoing Particulate / foreign matter F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0315-2026
Class II · Moderate risk

Estradiol

Presence of Foreign substance - potential presence of metal particulate matter

Ongoing Particulate / foreign matter F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0314-2026
Class II · Moderate risk

Estradiol

Presence of Foreign substance - potential presence of metal particulate matter

Ongoing Particulate / foreign matter F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0313-2026

Other recalls by Noven Pharmaceuticals Inc

All 2021 recalls
Class II · Moderate risk

Xelstrym (dextroamphetamine)

Defective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).

Ongoing Packaging defect Noven Pharmaceuticals Inc NDC 68968-0215-3 D-0055-2025